Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α‐synuclein
Open Access
- 24 January 2017
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 95 (9) , 1871-1887
Abstract
The α‐synuclein protein exists in vivo in a variety of covalently modified and aggregated forms associated with Parkinson's disease (PD) pathology. However, the specific proteoform structures involved with neuropathological disease mechanisms are not clearly defined. Since α‐synuclein plays a role in presynaptic neurotransmitter release, an in vitro enzyme‐based assay was developed to measure glutamate release from mouse forebrain synaptoneurosomes (SNs) enriched in synaptic endings. Glutamate measurements utilizing SNs from various mouse genotypes (WT, over‐expressers, knock‐outs) suggested a concentration dependence of α‐synuclein on calcium/depolarization‐dependent presynaptic glutamate release from forebrain terminals. In vitro reconstitution experiments with recombinant human α‐synuclein proteoforms including monomers and aggregated forms (fibrils, oligomers) produced further evidence of this functional impact. Notably, brief exogenous applications of fibrillated forms of α‐synuclein enhanced SN glutamate release but monomeric forms did not, suggesting preferential membrane penetration and toxicity by the aggregated forms. However, when applied to brain tissue sections just prior to homogenization, both monomeric and fibrillated forms stimulated glutamate release. Immuno‐gold and transmission electron microscopy (TEM) detected exogenous fibrillated α‐synuclein associated with numerous SN membranous structures including synaptic terminals. Western blots and immuno‐gold TEM were consistent with SN internalization of α‐synuclein. Additional studies revealed no evidence of gross disruption of SN membrane integrity or glutamate transporter function by exogenous α‐synuclein. Overall excitotoxicity, due to enhanced glutamate release in the face of either overexpressed monomeric α‐synuclein or extrasynaptic exposure to fibrillated α‐synuclein, should be considered as a potential neuropathological pathway during the progression of PD and other synucleinopathies.Keywords
Funding Information
- UCSD/UCLA Diabetes Research Center (P30 DK063491)
- U.S. Department of Energy, Office of Biological and Environmental Research (BER) program (DE-FC02-02ER63421)
This publication has 76 references indexed in Scilit:
- Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathiesJournal of Neurochemistry, 2015
- Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell deathCell Death & Differentiation, 2015
- α-Synuclein strains cause distinct synucleinopathies after local and systemic administrationNature, 2015
- Exogenous -Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine ReleaseJournal of Neuroscience, 2014
- Modeling Lewy pathology propagation in Parkinson's diseaseParkinsonism & Related Disorders, 2014
- α-Synuclein Can Inhibit SNARE-Mediated Vesicle Fusion through Direct Interactions with Lipid BilayersBiochemistry, 2013
- α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregationNature, 2011
- Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and ApolipoproteinsJournal of Biological Chemistry, 2010
- α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in VitroScience, 2010
- Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin LabelingJournal of Biological Chemistry, 2003